- NCIt
- C5111
Loading cancer entity…
Loading cancer entity…
Clinical trials
75 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06357377 | A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors | recruiting | Phase 1 | 12 | Neonc Technologies, Inc.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05919264 | FOG-001 in Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 619 | Parabilis Medicines, Inc.INDUSTRY | 2 | Aug 17, 2026 | clinicaltrials |
| Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma |
| recruiting |
| Phase 1 / Phase 2 |
| 57 |
| Nanfang Hospital, Southern Medical UniversityOTHER |
| 1 |
| Nov 18, 2025 |
| clinicaltrials |
Data updated 15 days agoSource updated Sep 15, 2026source: clinicaltrials